Cardiovascular risk and prevention in diabetes mellitus

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 10, Issue 5, 2010, Pages 495-499

  Roberts, Aled W ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; METFORMIN; PLACEBO; RAMIPRIL; SIMVASTATIN; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIABETIC HYPERTENSION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; LOW DRUG DOSE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; REVIEW; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 78650409247     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.10-5-495     Document Type: Review

References (29)

1. Kannel WB,McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 1979;2:120-6.
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44. (Pubitemid 23046633)
3. Dorman JS, Laporte RE, Kuller LH et al. The Pittsburgh insulin-dependent diabetes mellitus (IDDM) morbidity and mortality study. Mortality results. Diabetes 1984;33:271-6.
4. Orchard TJ, Costacou T, Kretowski A, Nesto RW. Type 1 diabetes and coronary artery disease. Diabetes Care 2006;29:2528-38. (Pubitemid 44912266)
5. Yorkshire and Humber Public Health Observatory (YHPHO). PBS Phase 3 Diabetes Population Prevalence Model, 1 April 2008. www.yhpho.org.uk/resource/ view.aspx?RID=81090. Accessed July 2010.
6. Wingard DL, Barrett-Connor E. Heart disease and diabetes. In: Harris MI, Cowie CC, Stern MP et al (eds). Diabetes in America, 2nd edn.Washington, DC: US Government Printing Office, 1995:429-48.
7. Faxon DP, Fuster V, Libby P et al. Atherosclerotic Vascular Diesease Conference: writing group III: pathophysiology. Circulation 2004;109:2617-25. (Pubitemid 38720566)
8. Fontbonne AM, Eschwege EM. Insulin and cardiovascular disease: Paris Prospective Study. Diabetes Care 1991;14:461-9.
9. Ludmer PL, Selwyn AP, Shook TL et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986;315:1046-51.
10. Nathan DM, Lachin J, Cleary P et al; Diabetes Control and Complications Trial; Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003;348:2294-303.
11. Anderson KM,Wilson PW, Odell PM, Kannel WV. An updated coronary risk profile. A statement for health professionals. Circulation 1991;83:356-62.
12. National Institute for Health and Clinical Excellence. Type 2 diabetes; the management of type 2 diabetes. London: NICE, 2008.
13. Hippisley-Cox J, Coupland C, Vinogradova Y et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008;336:1475-82. (Pubitemid 351977019)
14. Wei M, Gaskill SP, Haffner SM, Stern MP. Effects of diabetes and level of glycaemia on all-cause and cardiovascular mortality. Diabetes Care 1998;21:1167-72.
15. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes: UKPDS 34. Lancet 1998;352:854-65.
16. Control Group, Turnbull FM, Abraira C, Anderson RJ et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009;52:2288-98.
17. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
18. Gerstein HC, Miller ME, Byington RP et al; Action to Control Cardiovascular Risk in Diabetes Study Group,. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
19. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.
20. Duckworth W, Abraira C,Moritz T et al; VADT investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39.
21. Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH. Rosiglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007;(3):CD006063.
22. Tzoulaki I, Molokhia M, Curcin V et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009;339:b4731.
23. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.
24. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet 2000;355:253-9.
25. Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group.MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.
26. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to prevent Heart Attack Trial (ALLHAT-LLT). Major outcomes in highrisk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002;288:2981-97.
27. University of Oxford, Diabetes Trials Unit Website: UKPDS Risk Engine. www.dtu.ox.ac.uk/riskengine/index.php. Accessed July 2010.
28. Libby P, Nathan DM, Abraham K et al. Report of the National Heart, Lung and Blood Institute-National Institute of Diabetes and Digestive and Kidney Disease Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. Circulation 2005;111:3489-93. (Pubitemid 40923404)
29. Nathan DM, Cleary PA, Backlund JY et al; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53.